Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C L Fowler

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
The Journal of Pediatrics|November 1, 1992
Defining the population of human immunodeficiency virus-infected children at risk for Mycobacterium avium-intracellulare infectionL L Lewis, K M Butler, R N Husson, et al.
JAMA|January 24, 1998
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trialsS L Preston, G L Drusano, A L Berman, et al.
Antimicrobial Agents and Chemotherapy|September 3, 1999
Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patientsS C Piscitelli, K Spooner, B Baird, et al.
Journal of Pediatric Surgery|April 1, 1991
Enhanced resection and improved survival in murine neuroblastoma (C1300-NB) after preoperative immunotherapyC L Fowler, S P Brooks, R Squire, et al.
Antimicrobial Agents and Chemotherapy|May 21, 1998
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infectionS L Preston, G L Drusano, A L Berman, et al.
Antimicrobial Agents and Chemotherapy|October 23, 1997
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous dosesS C Chien, M C Rogge, L G Gisclon, et al.
Journal of Clinical Microbiology|August 21, 2009
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methodsM A Pfaller, D J Diekema, M A Ghannoum, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The Journal of Pediatrics|November 1, 1992
Defining the population of human immunodeficiency virus-infected children at risk for Mycobacterium avium-intracellulare infectionL L Lewis, K M Butler, R N Husson, et al.
JAMA|January 24, 1998
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trialsS L Preston, G L Drusano, A L Berman, et al.
Antimicrobial Agents and Chemotherapy|September 3, 1999
Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patientsS C Piscitelli, K Spooner, B Baird, et al.
Journal of Pediatric Surgery|April 1, 1991
Enhanced resection and improved survival in murine neuroblastoma (C1300-NB) after preoperative immunotherapyC L Fowler, S P Brooks, R Squire, et al.
Antimicrobial Agents and Chemotherapy|May 21, 1998
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infectionS L Preston, G L Drusano, A L Berman, et al.
Antimicrobial Agents and Chemotherapy|October 23, 1997
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous dosesS C Chien, M C Rogge, L G Gisclon, et al.
Journal of Clinical Microbiology|August 21, 2009
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methodsM A Pfaller, D J Diekema, M A Ghannoum, et al.
Pageof 4